Penpulimab is under clinical development by Akeso and currently in Phase II for Cervical Cancer. According to GlobalData, Phase II drugs for Cervical Cancer have a 35% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Penpulimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Penpulimab overview

Penpulimab is a monoclonal antibody with antineoplastic activity. It is formulated as solution for intravenous route of administration. Penpulimab is indicated for the treatment of patients with relapsed or refractory classic Hodgkin’s lymphoma (CHL) after at least second-line systemic chemotherapy treatment.
Penpulimab is under development for the treatment of recurrent, and metastatic cervical cancer, relapsed and refractory Hodgkin lymphoma, solid tumors including nasopharyngeal carcinoma, hepatocellular carcinoma, recurrent or metastatic colorectal cancer (second and third line), recurrent squamous cell carcinoma of the head and neck, recurrent gastric or gastroesophageal junction (GEJ) adenocarcinoma, metastatic urothelial carcinoma, gastrointestinal pancreatic neuroendocrine tumor, chest cancer, pheochromocytoma and paraganglioma (PPGL)  head and neck non-squamous cell cancer, metastatic head and neck non-squamous cell cancer, oropharyngeal cancer, hypopharyngeal cancer, laryngeal cancer, oral cavity (mouth) cancer, undifferentiated thyroid cancer, small cell lung cancer, recurrent or metastasis pleural mesothelioma and thymic cancer, squamous and non-squamous non-small cell lung cancer, gastroesophageal junction (GEJ) adenocarcinoma, esophageal squamous-cell carcinoma, metastatic adenocarcinoma of the pancreas, triple-negative breast cancer, hepatocellular carcinoma (HCC), microsatellite instability-high (MSI-H) colorectal cancer, pancreatic carcinoma, cholangiocarcinoma and glioblastoma multiforme. It is administered through intravenous route. The therapeutic candidate acts by targeting programmed cell death protein 1 (PD-1). It is developed based on antibody analytical platform. It was under development for gastric cancer.

Akeso overview

Akeso is a clinical-stage biopharmaceutical company that focuses on in-house discovery and development of mono and bi-specific antibody drugs. The company’s product pipeline includes Ak101 and Ak111 targeting plaque psoriasis; Ak102 for the treatment of hypercholesterolemia; Ak104 against cancer; Ak105 for treating anlotinib; and Ak112 against solid tumors. It also offers kangfang integrated development platform (ACE Platform) which covers all drug research and development, including target verification, antibody discovery and also development functions. The company works in partnership with MERCK & CO Inc, Dawnrays Pharmaceutical Holdings Ltd, Sino Biopharmaceutical Ltd and China Biopharma. Akeso is headquartered in Zhongshan, Guangdong, China

For a complete picture of Penpulimab’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.